Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HNS001
MIFTS: 34

Hansen's Disease

Categories: Neuronal diseases, Rare diseases, Skin diseases, Smell/Taste diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Hansen's Disease

About this section

MalaCards integrated aliases for Hansen's Disease:

Name: Hansen's Disease 52 3
Leprosy 52 71

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Skin diseases Smell/Taste diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 71 C0023343
Sources

Summaries for Hansen's Disease

About this section
NIH Rare Diseases : 52 Hansen's disease (also known as leprosy) is a rare bacterial infection that affects the skin, nerves and mucous membranes . After exposure, it may take anywhere from 2 to 10 years to develop features of the condition. Once present, common signs and symptoms include skin lesions ; muscle weakness or paralysis; eye problems that may lead to blindness; nosebleeds; severe pain; and/or numbness in the hands, feet, arms and legs. Hansen's disease is caused by the bacterium Mycobacterium leprae; however, the way in which the bacterium is transmitted (spread) is poorly understood. It appears that only about 5% of people are susceptible to the condition. Hansen's disease is easily treated with combination antibiotics for 6 months to 2 years.

MalaCards based summary : Hansen's Disease, also known as leprosy, is related to leprosy 1 and leprosy 5. An important gene associated with Hansen's Disease is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Dapsone and Rifampicin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

CDC : 3 Hansen's disease (also known as leprosy) is an infection caused by slow-growing bacteria called Mycobacterium leprae. It can affect the nerves, skin, eyes, and lining of the nose (nasal mucosa). With early diagnosis and treatment, the disease can be cured. People with Hansen's disease can continue to work and lead an active life during and after treatment. Leprosy was once feared as a highly contagious and devastating disease, but now we know it doesn't spread easily and treatment is very effective. However, if left untreated, the nerve damage can result in crippling of hands and feet, paralysis, and blindness.

Sources

Related Diseases for Hansen's Disease

About this section

Diseases related to Hansen's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 775)
# Related Disease Score Top Affiliating Genes
1 leprosy 1 12.8
2 leprosy 5 12.5
3 leprosy 2 12.5
4 leprosy 4 12.4
5 leprosy 3 12.2
6 trigeminal trophic syndrome 11.5
7 buruli ulcer 11.5
8 mycobacterium kansasii 11.5
9 chronic rhinitis 11.5
10 fetal thalidomide syndrome 11.5
11 mycobacterium abscessus 11.2
12 lepromatous leprosy 10.7
13 neuropathy 10.5
14 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
15 peripheral nervous system disease 10.4
16 tuberculoid leprosy 10.4
17 neuritis 10.4
18 autoimmune disease 10.3
19 arthritis 10.3
20 47,xyy 10.3
21 glomerulonephritis 10.2
22 tetanus 10.2
23 ectropion 10.2
24 paragangliomas 1 10.2
25 scabies 10.2
26 systemic lupus erythematosus 10.2
27 exanthem 10.2
28 uveitis 10.2
29 pulmonary tuberculosis 10.2
30 antiphospholipid syndrome 10.2
31 mycosis fungoides 10.2
32 leprosy 6 10.2
33 borderline leprosy 10.2
34 skin disease 10.2
35 yaws 10.2
36 48,xyyy 10.2
37 dysautonomia 10.2
38 crohn's disease 10.1
39 visceral leishmaniasis 10.1
40 malaria 10.1
41 infant gynecomastia 10.1
42 onchocerciasis 10.1
43 gynecomastia 10.1
44 hepatitis 10.1
45 tenosynovitis 10.1
46 autonomic dysfunction 10.1
47 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
48 indeterminate leprosy 10.1
49 arthropathy 10.1
50 syphilis 10.1

Graphical network of the top 20 diseases related to Hansen's Disease:



Diseases related to Hansen's Disease
Sources

Symptoms & Phenotypes for Hansen's Disease

About this section
Sources

Drugs & Therapeutics for Hansen's Disease

About this section

Drugs for Hansen's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4 80-08-0 2955
2
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
3 Vitamins Phase 4
4 Antibiotics, Antitubercular Phase 4
5 Antiprotozoal Agents Phase 4
6 Antiparasitic Agents Phase 4
7 Antimalarials Phase 4
8 Anti-Bacterial Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Immunosuppressive Agents Phase 4
11 Immunologic Factors Phase 4
12 Angiogenesis Inhibitors Phase 4
13
Amitriptyline Approved Phase 3 50-48-6 2160
14
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
15
Perphenazine Approved Phase 3 58-39-9 4748
16
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
17
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
18
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
19
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
20
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
21
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
22
Goserelin Approved Phase 3 65807-02-5 5311128 47725
23
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
24
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
25
Infliximab Approved Phase 3 170277-31-3
26
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
27
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
28
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
29
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946
30
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
31 Tocotrienol Investigational Phase 3 6829-55-6
32 Antidepressive Agents Phase 3
33 Narcotics Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Adrenergic Agents Phase 3
36 Analgesics Phase 3
37 Psychotropic Drugs Phase 3
38 Analgesics, Opioid Phase 3
39 Antipsychotic Agents Phase 3
40 Amitriptyline, perphenazine drug combination Phase 3
41 Antidepressive Agents, Tricyclic Phase 3
42 Hormones Phase 3
43 Antineoplastic Agents, Hormonal Phase 3
44 Cyclosporins Phase 2, Phase 3
45 Antifungal Agents Phase 2, Phase 3
46 Calcineurin Inhibitors Phase 2, Phase 3
47 Adjuvants, Immunologic Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
49 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
50 Androgens Phase 3

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L：A Multi-center Randomized Controlled Trial Unknown status NCT03519568 Phase 4
3 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
4 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
5 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
6 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
7 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Unknown status NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
8 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
9 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
10 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
11 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
12 Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) Completed NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
13 A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
15 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
16 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
17 Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan Recruiting NCT03651102 Phase 2, Phase 3 Thalidomide Oral Product
18 Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
19 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
20 Economic Evaluation of New MDR TB Regimens (PRACTECAL EE) Not yet recruiting NCT04207112 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Standard Drugs
21 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Not yet recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
22 To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus. Unknown status NCT02023411 Phase 2 Teriparatide
23 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
24 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
25 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00162760 Phase 2 Thalidomide
26 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
27 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
28 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
29 A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas Completed NCT00047879 Phase 2 Thalidomide
30 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
31 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
32 Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease Recruiting NCT02968212 Phase 2 Clofazimine
33 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
34 Umbilical Cord Serum Versus Conventional Eyedrops In Treatment of Moderate To Severe Dry Eye Disease: A Randomized Clinical Trial Not yet recruiting NCT04217785 Phase 1, Phase 2 Optive, Ophthalmic Solution;Genteal lubricant gel
35 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
36 A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. Terminated NCT00469703 Phase 2 Thalidomide
37 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
38 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
39 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
40 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
41 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
42 Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses Completed NCT02493283 Phase 1 Dapsone single dose;Dapsone multiple dose
43 A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG. Completed NCT00654316 Phase 1
44 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
45 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV Completed NCT00395720 Phase 1
46 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis. Completed NCT00456183 Phase 1
47 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
48 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
49 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
50 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437

Search NIH Clinical Center for Hansen's Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide
Sources

Genetic Tests for Hansen's Disease

About this section
Sources

Anatomical Context for Hansen's Disease

About this section

MalaCards organs/tissues related to Hansen's Disease:

40
Skin, Testes, T Cells, Eye, Bone, Liver, Monocytes
Sources

Publications for Hansen's Disease

About this section

Articles related to Hansen's Disease:

(show top 50) (show all 20754)
# Title Authors PMID Year
1
The implementation of an integrated e-leprosy framework in a leprosy control program at primary health care centers in Indonesia. 61
32497853 2020
2
Metabolism and interactions of antileprosy drugs. 61
32339493 2020
3
Immune Complex-Driven Generation of Human Macrophages with Anti-Inflammatory and Growth-Promoting Activity. 61
32434940 2020
4
A critical comparative ethnographic study of courtesy stigma in two leprosy-impacted communities in Indonesia. 61
31971879 2020
5
'Zero Leprosy' and other endgame strategies: Rhetoric vs. realism in public health campaigns. 61
32202468 2020
6
Leprosy: Clinical aspects and diagnostic techniques. 61
32229279 2020
7
Leprosy: Treatment and management of complications. 61
32244016 2020
8
Epidemiological profile and severity of erythema nodosum leprosum in Brazil: a cross-sectional study. 61
32358972 2020
9
Oral candida prevalence and species specificity in leprosy. 61
31796204 2020
10
Hematological alterations in lepromatous leprosy: A cross-sectional observational study. 61
31796205 2020
11
Current updates on dental perspectives of leprosy - Revisited. 61
31813526 2020
12
Update on the use of dapsone in dermatology. 61
31909480 2020
13
Sarcoidosis with cutaneous perineural granulomas and neurological manifestations: A potential mimicker of leprosy. 61
32022940 2020
14
Macular hypopigmentation, hair loss and follicular spongiosis: A distinct clinicopathological entity. 61
30688218 2020
15
Epidemiological aspects of leprosy. 61
31806242 2020
16
Clofazimine: an old drug for never-ending diseases. 61
32476494 2020
17
The immunology of other mycobacteria: M. ulcerans, M. leprae. 61
32100087 2020
18
Characteristics of Oral Lesions in Patients With Hansen Disease. 61
32574720 2020
19
Structure, stability and chaperone function of Mycobacterium leprae Heat Shock Protein 18 are differentially affected upon interaction with gold and silver nanoparticles. 61
32084461 2020
20
Pathological, ultrasonographic, and electrophysiological characterization of clinically diagnosed cases of pure neuritic leprosy. 61
32250546 2020
21
Nutritional status and morbidity profile of children with leprosy contact in a rural community. 61
32576099 2020
22
[When a wrist sprain leads to diagnosing leprosy - a case report]. 61
32531791 2020
23
Logotherapy towards self-esteem of leprosy patients at Tadjuddin Chalid Hospital in Makassar City. 61
32545100 2020
24
Response to "Three drugs are unnecessary for treating paucibacillary leprosy-A critique of the WHO guidelines". 61
32497033 2020
25
Novel PCR primers for improved detection of Mycobacterium leprae and diagnosis of leprosy. 61
31981442 2020
26
[Leprosy in Amazonas-impressions of the National Leprosy Program]. 61
32333041 2020
27
Genetics of leprosy: today and beyond. 61
31713021 2020
28
Caprine nodular thelitis due to Mycobacterium uberis: A series of 26 cases in 11 dairy goat farms in Western France. 61
32540717 2020
29
Human genetics of Buruli ulcer. 61
32266523 2020
30
Developing Feasible, Locally Appropriate Socioeconomic Support for TB-Affected Households in Nepal. 61
32532101 2020
31
Mycobacterium lepromatosis genome exhibits unusually high CpG dinucleotide content and selection is key force in shaping codon usage. 61
32512206 2020
32
Evaluation of the sub-acute toxicity of Acacia catechu Willd seed extract in a Wistar albino rat model. 61
32169672 2020
33
The risk of leprosy in patients using immunobiologics and conventional immunosuppressants for the treatment of dermatological and rheumatological diseases: A cohort study. 61
32564427 2020
34
A Case of Dapsone Hypersensitivity Syndrome in an Indian Leprosy Patient: Retrospective Screening Reveals the Genetic Connection with HLA-B*13:01. 61
32535989 2020
35
Real-time PCR-based quantitation of viable Mycobacterium leprae strain from clinical samples and environmental sources and its genotype in multi-case leprosy families of India. 61
32577954 2020
36
Genotyping of Mycobacterium leprae for understanding the distribution and transmission of leprosy in endemic provinces of China. 61
32553715 2020
37
Oro-facial manifestations in lepromatous leprosy patients in Central India: clinical findings from a cross-sectional study. 61
31435822 2020
38
Treatment of histoid leprosy: a lack of consensus. 61
32544270 2020
39
Analysis of HLA-G protein expression in leprosy. 61
32556498 2020
40
[Erratum to: Leprosy in Amazonas-impressions of the National Leprosy Program]. 61
32394078 2020
41
Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. 61
32555205 2020
42
Case Report: Leprosy Osteoarticular Alterations Mimicking Rheumatoid Arthritis. 61
32228782 2020
43
Cytokine gene polymorphisms in type I and type II reactions in Hansen's disease. 61
32372760 2020
44
Ultra-sensitive detection of Mycobacterium leprae: DNA extraction and PCR assays. 61
32453754 2020
45
Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial. 61
31997794 2020
46
Commingled crypts: Comparative health among Byzantine monastics in the Levant. 61
31907930 2020
47
Generation of two LRRK2 homozygous knockout human induced pluripotent stem cell lines using CRISPR/Cas9. 61
32339904 2020
48
Leprosy reactions in North-East Mexico: epidemiology and risk factors for chronic erythema nodosum leprosum. 61
31944428 2020
49
Molecular epidemiology and transmission dynamics of leprosy among multicase families and case-contact pairs. 61
32371193 2020
50
Epidemiological monitoring of leprosy indicators in Sergipe (2001-2015): segmented regression analysis. 61
32522447 2020
Sources

Variations for Hansen's Disease

About this section
Sources

Expression for Hansen's Disease

About this section
Search GEO for disease gene expression data for Hansen's Disease.
Sources

Pathways for Hansen's Disease

About this section
Sources

GO Terms for Hansen's Disease

About this section
Sources

Sources for Hansen's Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....